On this episode of BioTech IQ, Ammon interviews Paul Lammers the CEO of Triumvira about developing autologus cell therapies using their T-Cell Antigen Coupler Platform (TAC). During this insightful discussion Paul talks about how he started in the industry, running a biotech company in today's environment, and what sets Triumvira's T-Cell therapy apart from the rest! Don't miss it!

Show support for show https://www.buymeacoffee.com/biotechiq

Check out the books recommended by Paul:
CEO Excellence - https://amzn.to/3OGjI3G
The Emperor of All Maladies - https://amzn.to/3IDyZ1l

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

Bryan Kobel decided to pursue a career in biotech after seeing its massive opportunities to change the world. He sits down with Ammon Rivera to share how he translated his background as an investment banker into his role as the CEO of TC BioPharm, a company that develops cancer therapy. He opens up about finding his purpose in this space that allows him to save lives and molds him into a compassionate leader. Bryan also talks about their allogenic Gamma Delta T Cell therapy platform, which involves injecting isolated Gamma Delta T Cells to treat cancer-stricken patients. He explains how they are continuously evolving this method to make it cost-effective and easily accessible to underserved and economically disadvantaged individuals.

Support the show! https://www.buymeacoffee.com/biotechiq

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

In this episode of BioTech IQ Ammon shares some real stats on the state of the hiring market in Biotech/pharma. We discuss what both job seekers and hiring managers can do to increase their success when searching/hiring. Bringing innovative treatments that make a difference in the life of people is the goal but the business side of drug development is as complex as the science sometimes. Don't miss it!

Leave a review and share! Thanks!

Support the show here: https://www.buymeacoffee.com/biotechiq

https://thebiotechiqpodcast.com/

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

Cary Claiborne Sr. is the CEO of Adial Pharmaceuticals and member of the board. He also sits on the board for Nuerosense Therapeutics and CytRx. Cary holds an MBA from Villanova University. In this episode Cary shares how his interest in finance at an early age led him to become the CFO of a small biotech that led him to where he is today.

Support the show: https://www.buymeacoffee.com/biotechiq

Books that Cary referenced:
Holy Bible - https://amzn.to/3Y6um4W
Control Your Destiny or Someone Else Will - https://amzn.to/3ITDuWc

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

On this episode of BioTech IQ Ammon interviews Farahnaz Forozan, PhD, MB who is a 20 year veteran in the industry. She discussed how she immigrated from Iran to the United States, became a Phd, was the Head of Translational Development with BMS, to running her own consulting practice. She has taken all this experience and is driving innovation within biotech.

Don't miss it! It's about Innovation.

www.forozanoncogenconsulting.com

Support the show here: https://www.buymeacoffee.com/biotechiq

https://thebiotechiqpodcast.com/

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

Throughout many of the discussions on BioTech IQ it is clear that a combination of therapies is likely the answer to treating cancers and other diseases. This is a point well made by the guests on this episode of the show. CEO Jack Hoppin, PhD and Chief Scientific Officer, John Babich PhD are Co-Founders of Ratio Therapeutics. Both bring a successful background in biotech and not only discuss what their organization is doing but lessons they have learned as entrepreneurs in treatment development. 

Don't miss it!

Support the show here: https://www.buymeacoffee.com/biotechiq

https://thebiotechiqpodcast.com

Don't forget to check out the YouTube Channel! https://www.youtube.com/@biotechiqpodcast4943

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

Science will only get you so far in biotech. No matter how ingenious your products are, you will never succeed as a company if you don’t have all the pieces if business development in place. And there is no greater piece than the people piece. As the Chief People Officer of Biomea Fusion, Naomi Cretcher knows that company culture is what is going to make or break her company’s success. Despite everything that went on with COVID and with a recession looming, Naomi is confident that investing on their talent pool with pay off in terms of company success. She joins Ammon Rivera in this episode to tell us what it takes exactly to build an excellent company culture in a biotech company and why the act of building one will give any business its biggest ROI. Tune in!

Support the show: https://www.buymeacoffee.com/biotechiq

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

Ammon shares an update what has changed and why no new episodes have been release for the last couple of months. And discussing some interesting facts about the biotech industry and where it's headed from a hiring perspective.

Atlas 2022 Year in Review
https://youtu.be/LONM9ekseJ4

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

In this epsisode of BioTech IQ Ammon interviews the Chief Growth Officer of M2GEN Todd Johnson, MD. M2GEN partners with 18 of the nation’s leading cancer centers, through the Oncology Research Information Exchange Network® (ORIEN), to deliver oncology informatics-based solutions to accelerate therapy discovery, development and delivery of precision medicine. M2GEN is one of the only companies to ensure that patient data has been granted through consent.

M2GEN utilizes the IRB-approved protocol, Total Cancer Care®, that allows for enhanced patient engagement through the ability to re-contact patients and facilitates linkages across disparate sources of data, creating a research ecosystem which can significantly benefit patients and improve patient care. 

Listen to more interviews at thebiotechiqpodcast.com
Dan Sfera's interview with Ammon https://youtu.be/86MtcfBnUmg

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/

There isn’t a cure for cancer yet, but if everyone can come together, we may find that cure sooner rather than later. One biotech company that is trying to solve cancer is Qualigen Therapeutics. With their oncology therapeutics pipeline, they could be onto something with their leading asset QN-302. 

Join Ammon Rivera as he talks to the Chief Medical Officer of Qualigen Therapeutics, Tariq Arshad, MD, about where they are right now in their therapeutics pipeline. Learn why cancer is the greatest injustice and how Tariq is fighting to stop it. Find out more about their research in Qualigen Therapeutics when it comes to killing these cancer cells. Let's all come together and stop cancer.

Check me out on LinkedIn https://www.linkedin.com/in/ammonr/